DE2130346C3 - Unterstützende Mittel bei malignen Geschwulsterkrankungen und viricide Mittel - Google Patents
Unterstützende Mittel bei malignen Geschwulsterkrankungen und viricide MittelInfo
- Publication number
- DE2130346C3 DE2130346C3 DE2130346A DE2130346A DE2130346C3 DE 2130346 C3 DE2130346 C3 DE 2130346C3 DE 2130346 A DE2130346 A DE 2130346A DE 2130346 A DE2130346 A DE 2130346A DE 2130346 C3 DE2130346 C3 DE 2130346C3
- Authority
- DE
- Germany
- Prior art keywords
- percent
- agents
- weight
- solution
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 201000011510 cancer Diseases 0.000 title claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 3
- 230000003319 supportive effect Effects 0.000 title claims 3
- 230000003253 viricidal effect Effects 0.000 title claims 3
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- WURBFLDFSFBTLW-UHFFFAOYSA-N benzil Chemical compound C=1C=CC=CC=1C(=O)C(=O)C1=CC=CC=C1 WURBFLDFSFBTLW-UHFFFAOYSA-N 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims description 8
- 235000019400 benzoyl peroxide Nutrition 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 229940110456 cocoa butter Drugs 0.000 claims description 4
- 235000019868 cocoa butter Nutrition 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- -1 oxyethylene sorbitol monooleate Chemical compound 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical class CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims 3
- 239000010685 fatty oil Substances 0.000 claims 3
- 230000002421 anti-septic effect Effects 0.000 claims 2
- 239000004342 Benzoyl peroxide Substances 0.000 claims 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims 1
- 241000593528 Mimus Species 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000032677 cell aging Effects 0.000 claims 1
- 230000001066 destructive effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229940102223 injectable solution Drugs 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 239000007800 oxidant agent Substances 0.000 claims 1
- 230000027272 reproductive process Effects 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 239000000080 wetting agent Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 206010028851 Necrosis Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- WBJWXIQDBDZMAW-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carbonyl chloride Chemical compound C1=CC=CC2=C(C(Cl)=O)C(O)=CC=C21 WBJWXIQDBDZMAW-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- PYHXGXCGESYPCW-UHFFFAOYSA-N alpha-phenylbenzeneacetic acid Natural products C=1C=CC=CC=1C(C(=O)O)C1=CC=CC=C1 PYHXGXCGESYPCW-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000010907 mechanical stirring Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 238000012371 Aseptic Filling Methods 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010059605 Necrobiosis Diseases 0.000 description 1
- 208000015906 Necrobiotic disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- UKXSKSHDVLQNKG-UHFFFAOYSA-N benzilic acid Chemical compound C=1C=CC=CC=1C(O)(C(=O)O)C1=CC=CC=C1 UKXSKSHDVLQNKG-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000001345 embryopathic effect Effects 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005977 kidney dysfunction Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical group [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000007484 viral process Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES380951A ES380951A1 (es) | 1970-06-19 | 1970-06-19 | Procedimiento para la destruccion o inactivacion selectiva de virus, micoplasma y celulas en las cuales se haya produ- cido una alteracion del ph o del potencial redox, causada por virus, micoplasmas o neoformaciones. |
| GB6189970A GB1383293A (en) | 1970-12-30 | 1970-12-30 | Process and a preparation for combating diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE2130346A1 DE2130346A1 (de) | 1971-12-23 |
| DE2130346B2 DE2130346B2 (de) | 1975-01-23 |
| DE2130346C3 true DE2130346C3 (de) | 1975-09-25 |
Family
ID=26155786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2130346A Expired DE2130346C3 (de) | 1970-06-19 | 1971-06-18 | Unterstützende Mittel bei malignen Geschwulsterkrankungen und viricide Mittel |
Country Status (10)
| Country | Link |
|---|---|
| BE (1) | BE768704A (OSRAM) |
| CA (1) | CA969475A (OSRAM) |
| DE (1) | DE2130346C3 (OSRAM) |
| DK (1) | DK134583B (OSRAM) |
| FR (1) | FR2100796A1 (OSRAM) |
| HU (1) | HU164425B (OSRAM) |
| IE (1) | IE35373B1 (OSRAM) |
| LU (1) | LU63355A1 (OSRAM) |
| NL (1) | NL7108426A (OSRAM) |
| RO (1) | RO61124A (OSRAM) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4256763A (en) | 1978-09-19 | 1981-03-17 | Mchugh John E | Treatment of herpes simplex infections and acne |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4459307A (en) * | 1981-03-16 | 1984-07-10 | Mchugh John E | Antibacterial drug |
-
1971
- 1971-06-10 DK DK283071AA patent/DK134583B/da unknown
- 1971-06-16 RO RO67315A patent/RO61124A/ro unknown
- 1971-06-17 LU LU63355A patent/LU63355A1/xx unknown
- 1971-06-17 IE IE783/71A patent/IE35373B1/xx unknown
- 1971-06-18 DE DE2130346A patent/DE2130346C3/de not_active Expired
- 1971-06-18 FR FR7122320A patent/FR2100796A1/fr active Granted
- 1971-06-18 CA CA116,048A patent/CA969475A/en not_active Expired
- 1971-06-18 NL NL7108426A patent/NL7108426A/xx unknown
- 1971-06-18 BE BE768704A patent/BE768704A/xx unknown
- 1971-06-19 HU HUFU295A patent/HU164425B/hu unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4256763A (en) | 1978-09-19 | 1981-03-17 | Mchugh John E | Treatment of herpes simplex infections and acne |
Also Published As
| Publication number | Publication date |
|---|---|
| IE35373L (en) | 1971-12-19 |
| DE2130346B2 (de) | 1975-01-23 |
| NL7108426A (OSRAM) | 1971-12-21 |
| IE35373B1 (en) | 1976-01-21 |
| BE768704A (fr) | 1971-12-20 |
| LU63355A1 (OSRAM) | 1973-01-22 |
| HU164425B (OSRAM) | 1974-02-28 |
| RO61124A (OSRAM) | 1976-11-15 |
| DK134583C (OSRAM) | 1977-06-13 |
| CA969475A (en) | 1975-06-17 |
| FR2100796A1 (en) | 1972-03-24 |
| DE2130346A1 (de) | 1971-12-23 |
| DK134583B (da) | 1976-12-06 |
| FR2100796B1 (OSRAM) | 1975-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69028102T2 (de) | Antineoplastische lösung und verfahren zur behandlung von neoplasmen | |
| DE2513797C2 (de) | Pharmazeutische zusammensetzung | |
| DE69229318T2 (de) | Hydrierte Rizinusöl-enthaltende injizierbare Formulierungen mit verlängerter Wirkstoffabgabe | |
| DE69003906T2 (de) | Triacetin enthaltende, langwirkende injizierbare Zusammensetzungen. | |
| CH660969A5 (de) | Verwendung von thiadiazinverbindungen. | |
| DE3013632A1 (de) | Mittel und seine verwendung zur regulierung des knochenmetabolismus | |
| DE2621214B2 (de) | Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und dessen Mineralsalzen | |
| DE2512391C2 (de) | Mittel zur Behandlung der Mastitis in Milchtieren | |
| DE2802273C3 (de) | Verfahren zur Herstellung von Suppositorien aus Aminoglycid-Antibiotica | |
| DE69004532T2 (de) | Topisch anzuwendende Defibrotid enthaltende Arzneizubereitungen. | |
| DE3115080A1 (de) | Arzneimittel fuer die orale verabreichung und verfahren zu seiner herstellung | |
| EP0667152A1 (de) | Orale Verwendung von Calciumformiat zur Behandlung von Calciumdefizienz bei Tieren | |
| DE2130346C3 (de) | Unterstützende Mittel bei malignen Geschwulsterkrankungen und viricide Mittel | |
| DE3145488A1 (de) | Tier-arzneimittel | |
| DE19912436A1 (de) | Ibuprofen-Lösung | |
| US4046918A (en) | Treatment of cells | |
| US4046919A (en) | Treatment of cells | |
| DE3787448T2 (de) | Verwendung von Otiloniumbromid für die topische Anwendung im Gastrointestinaltrakt und entsprechende geeignete pharmazeutische Formulierung. | |
| DE2302659A1 (de) | Parenterales benzodiazepinhaltiges arzneimittel | |
| DE69132145T2 (de) | Peritoneal wirksame medikamente | |
| DE2401453A1 (de) | Pharmazeutische zusammensetzung zur behandlung von hautproliferationserkrankungen | |
| DE3044753C2 (OSRAM) | ||
| DE69731981T2 (de) | Neue verbesserte formulierung zur behandlung von thromboembolismus | |
| DE2262139A1 (de) | Arzneimittel zur bekaempfung von endoparasiten | |
| DE69001540T2 (de) | Arzneimittel zur rektalen verabreichung von calcitonin. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C3 | Grant after two publication steps (3rd publication) | ||
| E77 | Valid patent as to the heymanns-index 1977 | ||
| 8339 | Ceased/non-payment of the annual fee |